The Phase 1/2 trial is a first-in-human, open-label, multi-national study designed to evaluate the safety, tolerability, and efficacy of TSRA-196 in adults with AATD. Trial participants will receive a ...

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit ...

Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial ...

Hissing “shah!” and energetically making hand signals and grunting “Nu!” does not induce a sense of holiness. Sitting quietly ...

Mr. Davé Brings more than 20 Years of Experience in Creating Enterprise Value through Digital Transformation, Information Technology and Artificial Intelligence across ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and anticipated ...

AI therapeutics company built on causal biology, today announced the acquisition of CombinAbleAI and the launch of insitro's TherML™ (Therapeutic Machine Learning) platform. The acquisition, which is ...

Many of us like to think that we’re fairly smart. But it can be a very humbling experience when you’re in the presence of ...

No one knows exactly when Terrence Butler began keeping a journal, but there is a best guess. The first and only time someone ...

Acuitas Therapeutics, a leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, announced that it ...